Valuation: ICAD

Market Cap 106M 91.42M 86.28M 78.2M 147M 10.09B 148M 1.03B 396M 5.13B 397M 388M 16.29B P/E 2023
-9.35x
P/E 2024 -8.59x
Enterprise Value 88.75M 76.83M 72.52M 65.73M 123M 8.48B 124M 865M 333M 4.32B 333M 326M 13.7B EV / Sales 2023
1.47x
EV / Sales 2024 1.6x
Free-Float
99.32%
Yield 2023 *
-
Yield 2024 -
3 years 1.18
Extreme 1.18
4.02
5 years 1.05
Extreme 1.05
12.6
10 years 1.05
Extreme 1.05
21.44
Manager TitleAgeSince
Chief Executive Officer 61 2023-03-09
Director of Finance/CFO 54 2025-07-16
Corporate Secretary - 2025-07-16
Date Insider Type Main position Quantity % Market Cap. Importance
7/17/25 Issuer sale

Director

1,553,657 5.8540%
7/17/25 Issuer sale

Chief Financial Officer

158,488 0.5972%
7/17/25 Issuer sale

Chief Technology Officer

351,145 1.3231%
Change 5-day change 1-year change 3-year change Capi.($)
+3.75%-.--%-.--%+89.71% 106M
+0.62%-0.03%+27.98%+20.11% 225B
+1.55%-2.12%+6.95%-19.49% 141B
+2.38%+3.07%-15.95%+24.86% 130B
+4.82%-5.75%-56.14%-15.32% 62.29B
+1.99%-0.03%-18.12%-12.87% 49.39B
+1.36%-4.87%+10.25%+16.88% 48.63B
-0.09%-2.69%+19.12%+29.42% 41.42B
+0.41%+0.15%+38.80%+53.43% 40.12B
+2.16%-2.35%-17.45%+52.38% 31.23B
Average +0.74%-2.91%-0.46%+23.91% 76.98B
Weighted average by Cap. +0.10%-2.40%+4.05%+12.04%

Financials

2023 2024
Net sales 17.32M 14.99M 14.15M 12.83M 24.07M 1.65B 24.26M 169M 65.01M 842M 65.04M 63.6M 2.67B 19.61M 16.98M 16.02M 14.52M 27.25M 1.87B 27.47M 191M 73.6M 953M 73.64M 72.01M 3.03B
Net income -4.85M -4.2M -3.96M -3.59M -6.74M -463M -6.79M -47.27M -18.19M -236M -18.2M -17.8M -748M -5.62M -4.86M -4.59M -4.16M -7.81M -537M -7.87M -54.77M -21.08M -273M -21.09M -20.63M -867M
Net Debt -21.21M -18.36M -17.33M -15.71M -29.48M -2.03B -29.71M -207M -79.61M -1.03B -79.65M -77.89M -3.27B -16.84M -14.58M -13.76M -12.47M -23.41M -1.61B -23.6M -164M -63.23M -819M -63.26M -61.86M -2.6B
Logo ICAD
iCAD Inc is a United States‑based company. The Company develops artificial intelligence solutions designed to support healthcare providers in the detection and diagnosis of cancer. The company focuses on providing clinically proven AI technologies that assist medical professionals in identifying cancer earlier, improving diagnostic accuracy, and enhancing workflow efficiency. Its solutions include platforms for cancer detection, breast density assessment, and risk evaluation, enabling clinicians to analyze medical images and support patient care decisions. The company leverages advanced data, clinical evidence, and AI‑driven technologies to deliver tools that integrate into existing healthcare systems and assist in screening and diagnostic processes across global markets.
Employees
66
  1. Stock Market
  2. Stocks
  3. ICAD Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!